Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,799

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

Open access
Ruiz-Palacios, Guillermo M., Pérez-Schael, Irene, Velázquez, F. Raúl, Abate, Hector, Breuer, Thomas, Clemens, SueAnn Costa, Cheuvart, Brigitte, Espinoza, Felix, Gillard, Paul, Innis, Bruce L., Cervantes, Yolanda, Linhares, Alexandre C., López, Pío, Macías-Parra, Mercedes, Ortega-Barría, Eduardo, Richardson, Vesta, Rivera-Medina, Doris Maribel, Rivera, Luis, Salinas, Belén, Pavía-Ruz, Noris, Salmerón, Jorge, Rüttimann, Ricardo, Tinoco, Juan Carlos, Rubio, Pilar, Nuñez, Ernesto, Guerrero, M. Lourdes, Yarzábal, Juan Pablo, Damaso, Silvia, Tornieporth, Nadia, Sáez-Llorens, Xavier, Vergara, Rodrigo F., Vesikari, Timo, Bouckenooghe, Alain, Clemens, Ralf, De Vos, Béatrice, O'Ryan, Miguel · 2006 · New England Journal of Medicine

Abstract

BACKGROUND: The safety and efficacy of an attenuated G1P[8] human rotavirus (HRV) vaccine were tested in a randomized, double-blind, phase 3 trial. METHODS: We studied 63,225 healthy infants from 11 Latin American countries and Finland who received two oral doses of either the HRV vaccine (31,673 infants) or placebo (31,552 infants) at approximately two months and four months of age. Severe gastroenteritis episodes were identified by active surveillance. The severity of disease was graded with the use of the 20-point Vesikari scale. Vaccine efficacy was evaluated in a subgroup of 20,169 infants (10,159 vaccinees and 10,010 placebo recipients). RESULTS: The efficacy of the vaccine against severe rotavirus gastroenteritis and against rotavirus-associated hospitalization was 85 percent (P<0.001 for the comparison with placebo) and reached 100 percent against more severe rotavirus gastroenteritis. Hospitalization for diarrhea of any cause was reduced by 42 percent (95 percent confidence interval, 29 to 53 percent; P<0.001). During the 31-day window after each dose, six vaccine recipients and seven placebo recipients had definite intussusception (difference in risk, -0.32 per 10,000 infants; 95 percent confidence interval, -2.91 to 2.18; P=0.78). CONCLUSIONS: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteritis from any cause, and were not associated with an increased risk of intussusception. (ClinicalTrials.gov numbers, NCT00139347 and NCT00263666.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa052434

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

Metadata

Authors
Ruiz-Palacios, G. M., Pérez-Schael, I., Velázquez, F. R., Abate, H., Breuer, T., Clemens, S. C., Cheuvart, B., Espinoza, F., Gillard, P., Innis, B. L., Cervantes, Y., Linhares, A. C., López, P., Macías-Parra, M., Ortega-Barría, E., Richardson, V., Rivera-Medina, D. M., Rivera, L., Salinas, B., Pavía-Ruz, N., Salmerón, J., Rüttimann, R., Tinoco, J. C., Rubio, P., Nuñez, E., Guerrero, M. L., Yarzábal, J. P., Damaso, S., Tornieporth, N., Sáez-Llorens, X., Vergara, R. F., Vesikari, T., Bouckenooghe, A., Clemens, R., De Vos, B., & O'Ryan, M.
Venue
New England Journal of Medicine
Published
2006-01-05
Volume
354
Issue
1
Pages
11-22
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2170749337
Cited by
1,799
References
20
FWCI
92.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.